公开(公告)号：US20230234917A1

公开(公告)日：2023-07-27

申请号：US18001238

申请日：2021-06-09

Applicant: SENDA BIOSCIENCES, INC.

Inventor： Spencer Cory PECK ,  Jenny LIU ,  Timothy F. BRIGGS ,  John Robert PROUDFOOT ,  William MCELROY ,  Robert Walter MYERS ,  Steven John TAYLOR

IPC: C07C237/10 ,  A61P35/00 ,  C07K5/062 ,  C07D305/08 ,  C07C275/14 ,  C07C271/20 ,  C07F9/40 ,  C07F9/42 ,  C07C317/08 ,  C07F5/02 ,  C07C237/22 ,  C07D263/32 ,  C07D233/64 ,  C07D257/04 ,  C07D249/08 ,  C07D271/06 ,  C07D271/10 ,  C07D249/04 ,  C07C255/29 ,  C07D213/40 ,  C07D333/20 ,  C07D235/16

CPC classification number: C07C237/10 ,  A61P35/00 ,  C07K5/06026 ,  C07D305/08 ,  C07C275/14 ,  C07C271/20 ,  C07F9/4006 ,  C07F9/425 ,  C07C317/08 ,  C07F5/027 ,  C07C237/22 ,  C07D263/32 ,  C07D233/64 ,  C07D257/04 ,  C07D249/08 ,  C07D271/06 ,  C07D271/10 ,  C07D249/04 ,  C07C255/29 ,  C07D213/40 ,  C07D333/20 ,  C07D235/16 ,  C07C2601/14

Abstract: The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.

公开(公告)号：US20230295152A1

公开(公告)日：2023-09-21

申请号：US17756243

申请日：2020-11-20

Applicant: SENDA BIOSCIENCES, INC.

Inventor： Alessandra BARTOLOZZI ,  John Robert PROUDFOOT ,  Timothy BRIGGS ,  John MANCUSO ,  Karunakar Reddy BONEPALLY ,  Patrick BUREAU ,  Tianlin GUO ,  Maxence BOS ,  Anna BLOIS ,  Bernard LANTER ,  Steven John TAYLOR ,  Leonard BUCKBINDER ,  Francesca BARONE

IPC: C07D471/04 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00

Abstract: The present disclosure relates to compounds of formula (Ia) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling. These compounds may also be useful in treating cancer when administered in combination with at least one additional therapy.